Amorphous magnesium carbonate nanoparticles with strong stabilizing capability for amorphous ibuprofen

Area of Science:

• Pharmaceutical Science
• Materials Science
• Nanotechnology

Background:

• Amorphous formulations of active pharmaceutical ingredients (APIs) enhance solubility and dissolution.
• Stabilizing APIs in the amorphous state is crucial for improving bioavailability.
• Nanoparticle-based drug delivery systems offer potential for enhanced therapeutic efficacy.

Purpose of the Study:

• To investigate the use of amorphous magnesium carbonate nanoparticles for stabilizing APIs in the amorphous state.
• To evaluate the impact of this nanocomposite formulation on drug dissolution rates.
• To assess the biocompatibility and stability of the novel formulation.

Main Methods:

• Solid dispersion technique utilizing amorphous magnesium carbonate nanoparticles.
• High-throughput screening for amorphous state stabilization.
• In vitro dissolution testing comparing amorphous and crystalline states.
• In vitro biocompatibility assays using human dermal fibroblasts.
• Long-term stability testing over six months.

Main Results:

• High proportions of ibuprofen successfully stabilized in the amorphous state using 17% wt/wt amorphous magnesium carbonate nanoparticles.
• Achieved drug release rates 83 times faster compared to the crystalline form.
• Demonstrated in vitro biocompatibility of the magnesium carbonate nanoparticles.
• Verified formulation stability over a six-month storage period.

Conclusions:

• Amorphous magnesium carbonate nanoparticles effectively stabilize APIs in the amorphous state.
• This novel formulation significantly enhances drug dissolution and bioavailability.
• The nanocomposite approach presents a promising strategy for developing advanced pharmaceutical formulations.